Financial Information

This section of the Co-Diagnostics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  Co-Diagnosticsassumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQCODX
Beta(1.96)
Shares Outstanding28.9M
Average Volume (10 days)501.4K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)$1.57
Sales (TTM)$3.33
Book Value (MRQ)$3.02
Cash Flow (TTM)$1.88
Cash (MRQ)$72,383,753.00

Analyst Views

Current Mean RecommendationBuy
Strong Buy1
 
Buy0
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Eugene Durenard
Director
(2,000)
Sell
Sep 8, 2021
Brian L. Brown
Chief Financial Officer
5,000
Acquire
May 24, 2021
Dwight H Egan
Director, Chief Executive Officer
(5,628)
Dispose
May 24, 2021
Brian L. Brown
Chief Financial Officer
(1,524)
Dispose
May 24, 2021
Dwight H Egan
Director, Chief Executive Officer
12,500
Acquire
May 24, 2021

Recent SEC Filings

Insider Buy/Sell
Sep 22, 2021
Insider Buy/Sell
Aug 19, 2021
Insider Buy/Sell
Aug 16, 2021
Insider Buy/Sell
Aug 16, 2021
Company Events
Aug 12, 2021

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.

LATEST NEWS RELEASE

Co-Diagnostics is a molecular diagnostics company with a unique mathematical approach to DNA test design. Our products offer a unique value proposition, making the detection of infectious disease and genetic disorders far more affordable worldwide.

Click here to learn more

Co-Diagnostics, Inc.
2401 South Foothill Dr, Suite D
Salt Lake City, Utah 84109
United States

1 (801) 438-1036

info@codiagnostics.com

COMPANY

 

© 2016-2020 Co-Diagnostics, Inc. • All Rights Reserved.